Dummer R - Search Results

1

P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma.

Banik I, Ghosh A, Beebe E, Burja B, Frank Bertoncelj M, Dooley CM, Markkanen E, Dummer R, Busch-Nentwich EM, Levesque MP. Banik I, et al. Among authors: dummer r. Cancers (Basel). 2023 Jan 31;15(3):877. doi: 10.3390/cancers15030877. Cancers (Basel). 2023. PMID: 36765834 Free PMC article.

2

Sorafenib in melanoma.

Mangana J, Levesque MP, Karpova MB, Dummer R. Mangana J, et al. Among authors: dummer r. Expert Opin Investig Drugs. 2012 Apr;21(4):557-68. doi: 10.1517/13543784.2012.665872. Epub 2012 Mar 7. Expert Opin Investig Drugs. 2012. PMID: 22394203 Review.

3

Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy.

Rozati S, Naef L, Levesque MP, French LE, Dummer R. Rozati S, et al. Among authors: dummer r. J Immunother. 2013 Jan;36(1):52-6. doi: 10.1097/CJI.0b013e31827809c7. J Immunother. 2013. PMID: 23211621

4

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Das Thakur M, et al. Among authors: dummer r. Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9. Nature. 2013. PMID: 23302800 Free PMC article.

5

Melanoma immunotherapy: historical precedents, recent successes and future prospects.

Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. Raaijmakers MI, et al. Among authors: dummer r. Immunotherapy. 2013 Feb;5(2):169-82. doi: 10.2217/imt.12.162. Immunotherapy. 2013. PMID: 23413908 Review.

6

Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching.

Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MIG, Hemmi S, Dummer R, Levesque MP. Widmer DS, et al. Among authors: dummer r. J Invest Dermatol. 2013 Oct;133(10):2436-2443. doi: 10.1038/jid.2013.115. Epub 2013 Mar 8. J Invest Dermatol. 2013. PMID: 23474946 Free article.

7

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Guenova E, et al. Among authors: dummer r. Expert Opin Investig Drugs. 2014 Apr;23(4):457-67. doi: 10.1517/13543784.2014.876407. Epub 2014 Jan 8. Expert Opin Investig Drugs. 2014. PMID: 24397291 Review.

8

To B-(RAF) or not to be.

Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP. Dummer R, et al. J Invest Dermatol. 2014 May;134(5):1200-1201. doi: 10.1038/jid.2014.62. J Invest Dermatol. 2014. PMID: 24732335 Free article.

9

Basal cell carcinomas in a tertiary referral centre: a systematic analysis.

Dreier J, Cheng PF, Bogdan Alleman I, Gugger A, Hafner J, Tschopp A, Goldinger SM, Levesque MP, Dummer R. Dreier J, et al. Among authors: dummer r. Br J Dermatol. 2014 Nov;171(5):1066-72. doi: 10.1111/bjd.13217. Epub 2014 Oct 20. Br J Dermatol. 2014. PMID: 24974741

10

Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma.

Otsuka A, Dreier J, Cheng PF, Nägeli M, Lehmann H, Felderer L, Frew IJ, Matsushita S, Levesque MP, Dummer R. Otsuka A, et al. Among authors: dummer r. Clin Cancer Res. 2015 Mar 15;21(6):1289-97. doi: 10.1158/1078-0432.CCR-14-2110. Epub 2015 Jan 15. Clin Cancer Res. 2015. PMID: 25593302 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,030 results

Search Page

Filters